Not medical advice. HGH Fragment 176-191 is sold for research. This guide does not recommend dosing, diagnosis, or therapy.
HGH Fragment 176-191 is listed in our catalogue under “HGH / Somatropin.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet—still scientific, but faster to read than the full mechanism list below.
HGH Fragment 176-191 — C-terminal lipolytic domain of human growth hormone activating β3-adrenergic receptor-mediated lipolysis without IGF-1 effects.
Many readers want context before diving into pathways. The list below summarises what researchers and reviewers discuss—cells, animals, and (for some drug-class molecules) formal clinical trials. It is not a promise of results for any individual.
“Reported” means described in the literature, not recommended for personal use. Our peptides are for laboratory research only.
Growth-hormone axis peptides are researched for how they signal through the GH/IGF pathway in animals and cells. Studies focus on endocrine biology and metabolism, not on prescribing or outcomes in people.
Below are mechanistic bullet points as they appear in our product reference material -useful for researchers comparing pathways. They are not simplified health claims.
Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. ~5% degradation per year refrigerated. - see our storage guide for best practices on temperature, light, and shelf life.
Typical research dosing discussion (literature-style): 250–500 mcg subcutaneously · 1–2 times daily on empty stomach · Serum t½ ≈ 4 min (rapid amino-terminal truncation cascade); metabolic effects persist significantly beyond circulating peptide clearance; approximately 40% oral bioavailability demonstrated in animal models for related AOD-9604 variant. Administer fasted for optimal lipolytic signaling — insulin antagonizes cAMP/PKA activation.
For preparation, follow the step-by-step reconstitution guide and use the reconstitution calculator to confirm draw volumes. Review subcutaneous injection basics for technique, and always verify batch purity by reading the COA.
What is HGH Fragment 176-191 in plain language?
HGH Fragment 176-191 is a research peptide we catalogue under “HGH / Somatropin.” This article explains how scientists discuss it in published literature and what study types usually appear—not as a consumer product claim.
Does this page give medical advice or dosing instructions for HGH Fragment 176-191?
No. Content is for laboratory and research literacy only. It does not diagnose, treat, or prevent disease, and is not a dosing guide.
Where can I see purity, variants, and pricing for HGH Fragment 176-191?
Use the “View product” button to open the canonical shop listing for HGH Fragment 176-191, where specifications and research SKU details are shown.
What about online case reports, before-and-after stories, or forum “logs” for HGH Fragment 176-191?
Those sources are not peer-reviewed evidence. This guide focuses on preclinical literature and, where relevant, formal clinical trial programmes for drug-class molecules. Anecdotes may be interesting culturally; they are not a safe basis for dosing or medical decisions.
Open the shop listing for variants, purity notes, and research SKU details.
View productAlso known as: HGH Frag 176-191, AOD-9604 Precursor, GH Fragment, C-Terminal HGH Fragment, Lipolytic Fragment, Fat Loss Fragment, Tyr-hGH177-191